Saad Harti
CEO, Chairman
Switzerland
Saad is Chairman and & CEO of Legacy Healthcare, a company he co-founded in 2016. Prior to that he was founder and CEO of Altacare, a distributor of innovative healthcare products servicing 60 markets around the world. He served as Chief Financial Officer of HRA Pharma a fast-growing consumer healthcare company with a focus on women’s health, contraception and compromised skin. He worked as a Director, audit & transactions for Arthur Anderson and began his career in medical marketing as an Assistant Product Manager for Glaxo SmithKline. Saad has an MBA from NEOMA Business School in France.

Bruce Patsner MD, JD
Medical
US
Bruce Patsner M.D. J.D. is a cancer surgeon, law Professor and former Senior Medical Officer at FDA with more than 15 years Pharma experience in clinical trial design, new prescription drug approval and pharmacovigilance, and regulation of drugs, devices, and biologics. While at FDA he was responsible for the approval of several new prescription drugs in women’s health and Oncology and reviewed more than 50 INDs. He is also a current member of the Editorial Board of the prestigious law journal Food and Drug Law.

Saad Harti
Founder & Chairman
Switzerland
Saad has started in the financial field, at Arthur Andersen.He later co-founded Altacare, a healthcare business development firm active in more than 50 markets. Saad has pioneered contraceptive-access programs in developing countries. Saad is the founder of Legacy and manages the company.

Alexandre Guichard
Clinical
Switzerland
Dr. Alexandre Guichard, PharmD, Ph D is an expert in dermatology, having participated in several clinical trials focusing on scalp disorders. Prior to Legacy Healthcare, Dr. Guichard was the manager and founder of the Trichology Unit at Besançon University Hospital (FR)

Marcos Val
CFO
Switzerland
Marcos spent 15 years in Healthcare and FMCG blue-chip corporates. Within biopharma, as Medtronic director, he did launch multi-million revenue programs. He later built a track-record raising funds for startups and carrying due diligence work for impact, until joining Legacy in 2017.

Geert Cauwenbergh
PhD
Director
US
Geert is a co-founder of Legacy Healthcare and a Board member. He is founder and senior managing partner of Phases123, an advisory firm in biotech and healthcare, and serves on the Boards of Genomic Expression and Barcode -Nano. Prior to that he was President & CEO of Phio Pharma, a company he took public, first on the OTC Markets, and later in an upgrade to NASDAQ, and served on the Boards of Cutanea Life Sciences, Phosphagenics, Moberg Pharma, Ogeda, Ablynx, ECI Biotech and BioNJ. Geert was Chairman and CEO of RHEI Pharma and was founder, CEO and Chairman of Barrier Therapeutics, a company he took public on NASDAQ. He served as Vice President of R&D for J&J’s consumer health business and as worldwide director of dermatology and infectious diseases at Janssen. Geert has a M. Sc. And Dr. Med Sc from KU Leuven University in Belgium.

Johanne Barthelet
Director
Switzerland
Johanne is co-founder of Legacy Healthcare and serves as a Board member. For 16 years she served as CEO of Tremail, a Swiss-based global freight forwarding and overseas logistics partner for the Swiss premium watch ecosystem with subsidiaries in Europe and Hong Kong, which she sold to a global logistics company. Prior to that she worked for PWC where she focused on transaction services. She served as a consultant for Valtech focused on leveraging technology to maximize branding and positioning. Johanne studied at INSEEC business school in Paris, France.

Peter Nicholson
Peter serves as an independent Board Member for Legacy Healthcare. He is Managing Director of ALTEKA, a boutique consulting firm focused on strategy and value maximization for the healthcare sector. He served for almost 5 years as Senior Vice President of Global Business Development and General Manager of Dermavant (Organon). For ten years he led the strategy, business development and alliance management functions for Galderma. He was responsible for business development and investor relations at Mentor (Johnson & Johnson) and held a similar role at INAMED (Allergan).
He was co-founder, CEO and board member of Blue Heron Bio (Eurofins Genomics). Peter received his BA in biochemistry, from the UC Berkeley and his MBA from UCLA.

Bernard Lignon
Director
Bernard started his career in pharma sales and marketing. He managed the European and African affiliates of several pharmaceutical firms (Sanofi, Akzo, etc.). He has been in charge of the communication of Pierre Fabre, one the largest independent European pharma, and a pioneer of botanical-based treatment and oncology.

Michel Chrétienne PharmD
Director
Michel Chrétienne, PharmD is member of the French Academy of Pharmacy. He spent 30 years as Pharmaceutical Director at Roussel (now Sanofi).

Saad Harti
CEO, Chairman
Switzerland
Saad is Chairman and & CEO of Legacy Healthcare, a company he co-founded in 2016. Prior to that he was founder and CEO of Altacare, a distributor of innovative healthcare products servicing 60 markets around the world. He served as Chief Financial Officer of HRA Pharma a fast-growing consumer healthcare company with a focus on women’s health, contraception and compromised skin. He worked as a Director, audit & transactions for Arthur Anderson and began his career in medical marketing as an Assistant Product Manager for Glaxo SmithKline. Saad has an MBA from NEOMA Business School in France.

Nadine Vincent
PharmD
Head of Regulatory Affairs
France
Dr. Nadine Vincent, PharmD is a pharmacist with 40 years’ experience in Regulatory Affairs at large pharma and medium-sized biotechs. Nadine has contributed to achieving FDA and EMA approval for 6 drugs.

Vergio Julien
Guiraud
Vergio is a multidisciplinary advisory fun in life-sciences founded by Julien Guirault

Pr.William Pralong
MD PhD
Chief Scientific Officer
Switzerland
Prof. em. EPLF, Bioengineering, QAQC
Scientific Advisor for Quality and Research

Cécile Bernier
Director
Switzerland
Cécile Bernier is an expert in formulation and manufacturing and has over 10 years’ experience in developing formulations. She oversaw already the manufacturing of 125 industrial batches of Coacillium during pre-marketing period.

Marco Ruedi
Chief Medical Officer
Switzerland
With over 20 years' experience in clinical trial development in a range of therapeutic areas including neurology, oncology and women's health. Involving the management of clinical studies, in particular through close collaboration with contract research organizations (CROs) and third-party suppliers, as well as preparation for inspections by the competent authorities.

Jiawei Liu PhD
Head of R&D, Drug Discovery
Switzerland
Dr. JiaWei Liu’s expertise lies in molecular biology, dermatology, cardiovascular and oncology domains, with over 20 years’ preclinical and clinical research and teaching experience at high ranking academic institutes (Universities and Hospitals Geneva, Lausanne, Harvard Medical School, Shanghai Institute of Materia Medica) and pharmaceutical companies (Debiopharm and Astellas). In addition to numerous peer-reviewed scientific publications, he is the co-inventor of several U.S. and worldwide patents that hold high potential commercial value.

Michel Chrétienne
PharmD
Director of Quality Pharmaceutical Development
France
Michel Chrétienne, PharmD is member of the French Academy of Pharmacy. He spent 30 years as Pharmaceutical Director at Roussel (now Sanofi). He then spent more than 10 years at HRA Pharma, a specialty pharma, as Qualified person in charge of Quality System and batch release.

Chris Cambourg
IT & Technical Director
Switzerland
Around 20 years career in the pharma industry with broad experience in the IT & Technology field. Chris Cambourg is an expert devising and establishing IT policies and systems to support the implementation of strategies set by the company.

Tatiana Rossetti
Director of Clinical Operations
Switzerland
Senior Clinical Development Professional with a 26-year history of working in the pharmaceutical industry. Extensive expertise in strategic planning for new drug development from a Clinical Operational perspective. A proven track record of success in global international programs, working in both contract research organizations (CROs) and biopharmaceutical companies, and achieving successful FDA and EMA drug marketing approvals.

Emmanuel Baert
Country Manager France
France
Emmanuel has almost 25 years of experience in pharmaceutical particularly in rare disease. He managed the operations in France (LFB Biomedicaments , Menarini Hospital for Melinta therapeutics) and launched activities in Latin America (LFB Biomedicaments, Servier). Today, he is Country Manager France, coordinates the European market access and pre-launch..

Tadafumi Shiiba
Country Manager
Japan
Tadafumi Shiiba, General Manager for Legacy Healthcare KK (Japan), has been working for medical corporations for more than 20 years with experiencing to manage two clinical trials on the product in Japan

Dr. med. Ulrike Blume-Peytavi
Germany
Investigator
Clinical Research Centre for Hair and Skin approach Charité-Universitätsmedizin

Juhee Cho
PhD
Investigator
Korea
Investigator for Permanent Chemotherapy-Induced Alopecia

Dr. Khalil Zaman
Investigator
Switzerland
CHUV- Investigator for Chemotherapy-Induced Alopecia

Prof. Bianca Maria Piraccini
Investigator
Italy
University of Bologna Dermatology Department of Specialized, Experimental and Diagnostic Medicine.

Dr. Leorey N. Saligan
Investigator
US
Maryland, US National Institutes of Health
Investigator for Cancer-Related Fatigue

Yasuyuki Kojima, MD, PhD
Investigator
Japan
St Marianna University School of Medicine
Investigator for Chemotherapy-Induced Alopecia trial

Pr. Kurt Hostettman
Advisor
Switzerland
Prof.em. UniGe and Unil, Pharmacy
Scientific Advisor for development of New Botanical Entities

Dr Liliane Laroche
Advisor
France
Michel has served as Pharmaceutical Director and Pharmacist in charge at Hoechst Marion Roussel (Aventis) until 1999. Michel is involved in a number of professional and scientific societies such as the French Association of Regulatory Affairs, Member of the Ethic Committee and Mediation of the French pharmaceutical industry (CEMIP) etc. Michel is responsible of the quality and manufacturing affairs of Legacy.